|12.18||+1.24||+11.33%||Vol 6.32M||1Y Perf 8.75%|
|Aug 5th, 2022 16:00 DELAYED|
|- -||-0.48 -3.94%|
|Target Price||15.14||Analyst Rating||Strong Buy 1.29|
|Potential %||24.30||Finscreener Ranking||★ 41.81|
|Insiders Trans % 3/6/12 mo.||-100/-100/-78||Value Ranking||★ 38.68|
|Insiders Value % 3/6/12 mo.||-100/-100/-98||Growth Ranking||★ 38.44|
|Insiders Shares Cnt. % 3/6/12 mo.||-100/-100/-98||Income Ranking||— -|
|Price Range Ratio 52W %||93.30||Earnings Rating||Sell|
|Market Cap||3.41B||Earnings Date||4th Aug 2022|
Today's Price Range
5 Year PE Ratio Range
|Moving Averages:||Strong Buy|
|Mngmt Effectiveness||Value||Industry||S&P 500||US Markets|
ROE (5Y Avg)
ROE last 12 Months
ROA (5Y Avg)
ROA last 12 Months
ROC (5Y Avg)
ROC last 12 Months
Return on invested Capital Q
Return on invested Capital Y
|Earnings History||Estimate||Reported||Surprise %|
|Earnings Per End||Estimate||Revision %||Trend|
|Next Report Date||-|
|Estimated EPS Next Report||-0.23|
|EPS Growth Next 5 Years %||-|
|Avg. Weekly Volume||3.53M|
|Avg. Monthly Volume||3.08M|
|Avg. Quarterly Volume||3.69M|
Amicus Therapeutics Inc. (NASDAQ: FOLD) stock closed at 12.18 per share at the end of the most recent trading day (a 11.33% change compared to the prior day closing price) with a volume of 6.32M shares and market capitalization of 3.41B. Is a component of indices and it is traded on NASDAQ exchange. The company belongs in the Biotechnology industry, Healthcare sector and employs 584 people. Amicus Therapeutics Inc. CEO is John F. Crowley.
The one-year performance of Amicus Therapeutics Inc. stock is 8.75%, while year-to-date (YTD) performance is 5.45%. FOLD stock has a five-year performance of -7.94%. Its 52-week range is between 5.91 and 12.63, which gives FOLD stock a 52-week price range ratio of 93.30%
Amicus Therapeutics Inc. currently has a PE ratio of -11.20, a price-to-book (PB) ratio of 12.74, a price-to-sale (PS) ratio of 12.48, a price to cashflow ratio of -, a PEG ratio of 2.32, a ROA of -33.93%, a ROC of -36.39% and a ROE of -113.58%. The company’s profit margin is -90.94%, its EBITDA margin is -69.30%, and its revenue ttm is $240.41 Million , which makes it $0.86 revenue per share.
Of the last four earnings reports from Amicus Therapeutics Inc., there were 1 positive earnings surprise and 3 negative earnings surprise. The company has EPS estimate of $-0.23 for the next earnings report. Amicus Therapeutics Inc.’s next earnings report date is -.
The consensus rating of Wall Street analysts for Amicus Therapeutics Inc. is Strong Buy (1.29), with a target price of $15.14, which is +24.30% compared to the current price. The earnings rating for Amicus Therapeutics Inc. stock is Sell (calculated from actual period earnings estimates revision (80% weight) and previous period earnings surprise (20% weight)).
Amicus Therapeutics Inc. has a dividend yield of -% with a dividend per share of $- and a payout ratio of -%.
Amicus Therapeutics Inc. has a Buy technical analysis rating based on Technical Indicators (ADX : 29.42, ATR14 : 0.69, CCI20 : 192.28, Chaikin Money Flow : 0.08, MACD : 0.21, Money Flow Index : 52.31, ROC : 10.93, RSI : 48.56, STOCH (14,3) : 83.36, STOCH RSI : 1.00, UO : 60.16, Williams %R : -16.64), Simple Moving Averages and Exponential Moving Averages.
Aggregated Insider Trades of Amicus Therapeutics Inc. in the last 12-months were: Bradley L. Campbell (Option Excercise at a value of $553 633), Bradley L. Campbell (Sold 140 200 shares of value $1 479 573 ), Burke W. Whitman (Buy at a value of $47 196), Daphne Quimi (Sold 4 396 shares of value $39 564 ), Ellen S. Rosenberg (Sold 22 245 shares of value $222 745 ), Glenn P. Sblendorio (Option Excercise at a value of $71 850), John F. Crowley (Option Excercise at a value of $1 047 643), John F. Crowley (Sold 600 842 shares of value $6 476 771 ), Margaret G. McGlynn (Option Excercise at a value of $71 850), Margaret G. McGlynn (Sold 15 000 shares of value $104 897 ), Michael G. Raab (Option Excercise at a value of $71 850), Michael G. Raab (Sold 15 000 shares of value $104 891 ), Samantha Prout (Option Excercise at a value of $48 004), Samantha Prout (Sold 9 970 shares of value $114 663 )
Thu, 04 Aug 2022 19:25 GMT Amicus (FOLD) Receives a Hold from Needham- TipRanks. All rights reserved.
Tue, 10 May 2022 04:45 GMT Analysts Are Bullish on Top Healthcare Stocks: Amicus (FOLD), Cerus (CERS)- TipRanks. All rights reserved.
Thu, 06 Jan 2022 16:25 GMT Amicus (FOLD) Receives a Hold from Berenberg Bank- TipRanks. All rights reserved.
Copyright © 2016-2022 Finscreener.org. All Rights Reserved.
Disclaimer: Before deciding to trade you should carefully consider your investment objectives, level of experience and your risk appetite. Forex and Tradegate data is a real-time with a 30 second refresh. Prices may not be accurate and may differ from the actual market price. Prices on the website are indicative and solely for informational purposes, not for trading purposes or advice. Please be aware of the risks associated with trading the on financial markets, it is one of the riskiest investment forms. Past performance does not guarantee future profits. We take no responsibility for any losses that may arise as a result of the data contained on this website. The content and the website are provided "as is", without any warranties. In no event will Finscreener.org, its employees, owners, directors, affiliates, partners, data provider, third party or anyone else liable to anyone else for any decision made regarding information on this website.
This could take some time, please wait.